127 related articles for article (PubMed ID: 29376759)
21. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
[TBL] [Abstract][Full Text] [Related]
22. Self-Assembling Derivative of Hydrocortisone as Glucocorticoid Receptor-Targeted Nanotherapeutics for Synergistic, Combination Therapy against Colorectal Tumor.
Sridharan K; Rathore B; Yousuf M; Reddy Rachamalla HK; Jinka S; Jaggarapu MMCS; Banerjee R
Mol Pharm; 2021 Mar; 18(3):1208-1228. PubMed ID: 33371687
[TBL] [Abstract][Full Text] [Related]
23. Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines.
Jinturkar KA; Anish C; Kumar MK; Bagchi T; Panda AK; Misra AR
Biomaterials; 2012 Mar; 33(8):2492-507. PubMed ID: 22200537
[TBL] [Abstract][Full Text] [Related]
24. Design and synthesis of pyrrolobenzodiazepine-gallic hybrid agents as p53-dependent and -independent apoptogenic signaling in melanoma cells.
Chou YW; Senadi GC; Chen CY; Kuo KK; Lin YT; Wang JJ; Lee JH; Wang YC; Hu WP
Eur J Med Chem; 2016 Feb; 109():59-74. PubMed ID: 26756315
[TBL] [Abstract][Full Text] [Related]
25. Noscapinoids bearing silver nanocrystals augmented drug delivery, cytotoxicity, apoptosis and cellular uptake in B16F1, mouse melanoma skin cancer cells.
Soni N; Jyoti K; Jain UK; Katyal A; Chandra R; Madan J
Biomed Pharmacother; 2017 Jun; 90():906-913. PubMed ID: 28441716
[TBL] [Abstract][Full Text] [Related]
26. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
[TBL] [Abstract][Full Text] [Related]
27. Zinc Induces Apoptosis of Human Melanoma Cells, Increasing Reactive Oxygen Species, p53 and FAS Ligand.
Provinciali M; Pierpaoli E; Bartozzi B; Bernardini G
Anticancer Res; 2015 Oct; 35(10):5309-16. PubMed ID: 26408691
[TBL] [Abstract][Full Text] [Related]
28. Hsp90-targeted miRNA-liposomal formulation for systemic antitumor effect.
Pore SK; Choudhary A; Rathore B; Ganguly A; Sujitha P; Kumar CG; Agawane SB; Kumar JM; Scaria V; Pillai B; Banerjee R
Biomaterials; 2013 Sep; 34(28):6804-17. PubMed ID: 23773821
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen guided liposomes for targeting encapsulated anticancer agent to estrogen receptor positive breast cancer cells: in vitro and in vivo evaluation.
Jain AS; Goel PN; Shah SM; Dhawan VV; Nikam Y; Gude RP; Nagarsenker MS
Biomed Pharmacother; 2014 May; 68(4):429-38. PubMed ID: 24721327
[TBL] [Abstract][Full Text] [Related]
30. Targeted drug delivery utilizing protein-like molecular architecture.
Rezler EM; Khan DR; Lauer-Fields J; Cudic M; Baronas-Lowell D; Fields GB
J Am Chem Soc; 2007 Apr; 129(16):4961-72. PubMed ID: 17397150
[TBL] [Abstract][Full Text] [Related]
31. SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival.
Fenouille N; Puissant A; Tichet M; Zimniak G; Abbe P; Mallavialle A; Rocchi S; Ortonne JP; Deckert M; Ballotti R; Tartare-Deckert S
Oncogene; 2011 Dec; 30(49):4887-900. PubMed ID: 21685937
[TBL] [Abstract][Full Text] [Related]
32. Nanoparticle-mediated drug delivery for treating melanoma.
Mundra V; Li W; Mahato RI
Nanomedicine (Lond); 2015; 10(16):2613-33. PubMed ID: 26244818
[TBL] [Abstract][Full Text] [Related]
33. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
34. A Novel Folate-Targeted Nanoliposomal System of Doxorubicin for Cancer Targeting.
Lohade AA; Jain RR; Iyer K; Roy SK; Shimpi HH; Pawar Y; Rajan MG; Menon MD
AAPS PharmSciTech; 2016 Dec; 17(6):1298-1311. PubMed ID: 26689406
[TBL] [Abstract][Full Text] [Related]
35. Effective Skin Cancer Treatment by Topical Co-delivery of Curcumin and STAT3 siRNA Using Cationic Liposomes.
Jose A; Labala S; Ninave KM; Gade SK; Venuganti VVK
AAPS PharmSciTech; 2018 Jan; 19(1):166-175. PubMed ID: 28639178
[TBL] [Abstract][Full Text] [Related]
36. Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma.
Yu Y; Wang ZH; Zhang L; Yao HJ; Zhang Y; Li RJ; Ju RJ; Wang XX; Zhou J; Li N; Lu WL
Biomaterials; 2012 Feb; 33(6):1808-20. PubMed ID: 22136714
[TBL] [Abstract][Full Text] [Related]
37. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
[TBL] [Abstract][Full Text] [Related]
38. Nanohybrid magnetic liposome functionalized with hyaluronic acid for enhanced cellular uptake and near-infrared-triggered drug release.
Nguyen VD; Zheng S; Han J; Le VH; Park JO; Park S
Colloids Surf B Biointerfaces; 2017 Jun; 154():104-114. PubMed ID: 28329728
[TBL] [Abstract][Full Text] [Related]
39. In vitro optimization of liposomal nanocarriers prepared from breast tumor cell specific phage fusion protein.
Wang T; Kulkarni N; Bedi D; D'Souza GG; Papahadjopoulos-Sternberg B; Petrenko VA; Torchilin VP
J Drug Target; 2011 Sep; 19(8):597-605. PubMed ID: 21275826
[TBL] [Abstract][Full Text] [Related]
40. Construction of a two-in-one liposomal system (TWOLips) for tumor-targeted combination therapy.
Su T; Long Y; Deng C; Feng L; Zhang X; Chen Z; Li C
Int J Pharm; 2014 Dec; 476(1-2):241-52. PubMed ID: 25300591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
